DNAprint Genomics (DNAG)

[worktoplay]

Technically, in the year 2000 they started the project looking to classify responders vs non-responders (efficacy of response) AND to produce methods capable of inferring a patient's susceptibility to an ADR. The original patent filed in 2002 covers methods to classify efficacy of the drug in patients and infer hepatocellular damage.

Both the Myalgia and negative response to ACE Inhibitors came later. They were the subjects of a new patent filed with the U.S. Patent Office on November 12, 2004. That patent was filed Internationally on November 2, 2005.

As I've already posted, their 10KSB filed on 3/29/06 tells us that:

http://www.sec.gov/Archives/edgar/data/1127354/000123174206000203/dnag10ksb.htm

Statinome: During 2005, we began a study with Genomics Collaborative Division of Seracare Life Sciences Inc. that also included the statinome program. Samples have been received from them and used to conduct a validation of the test. An abstract was presented at the last meeting of the American Society of Clinical Pharmacology and Therapeutics (March, 10, 2006 in Baltimore). Also, a paper has been prepared and submitted for publication.

I don't think it takes a rocket scientist to figure out that the upcoming JPG article is the article referred to above (You DO realize that the Peer Review process takes months, right?). The article would have been written AFTER completing the validation study, and the validation study would have taken place AFTER the discovery. Now since the validation study took place in 2005, I think it's safe to say that the discovery was actually made PRIOR to 2005, and would quite plausibly, if not undoubtedly be the subject of that November 2004 patent, which was quite probably updated with the validation data when it was filed internationally in November 2005.

Now, are you keeping up with me or do I need to go a l i t t l e s l o w e r...

Later,
W2P